Improving patients’ quality of life is central to Horus Pharma’s DNA

Horus Pharma was founded on the French Riviera, between Sophia Antipolis and Monaco. After several years in R&D, business development and the management of pharmaceutical companies, founders Martine and Claude Claret, two pharmacists with a passion for ophthalmology, decided to take the plunge, driven by their desire for independence and their commitment to advancing eye health through rigour and innovation.

They founded their own company, dedicated entirely to ophthalmology. The name they chose was inspired by Horus, the Egyptian god whose left eye was believed to have healing powers: a reference that reflects their ambition to preserve vision.

Horus Pharma is all about ambition

Martine and Claude Claret

Our ambition at Horus Pharma is to remain curious and open-minded in order to deliver effective, innovative solutions and services to patients with eye diseases and healthcare professionals.

Martine and Claude ClaretPresident and CEO of Horus Pharma
Design Sans Titre (8)

  • Family governance as a driver of responsiveness and stability

    Family governance is one of Horus Pharma’s defining characteristics and a key strength of the company. Martine and Claude Claret have passed on to their sons, Nicolas (on the left in the photo) and Adrien (on the right), the values of closeness and innovation that have underpinned their work for more than two decades. Their collaboration is built on complementary strengths and independence, principles that are integral to the company’s family governance.
    It gives Horus Pharma both stability and agility, enabling the company to work effectively over the long term, which is essential in this sector.

    Join Us

  • A solution maker working closely with healthcare professionals and their patients

    With these strengths, Horus Pharma is now a major player in ophthalmology in Europe. As the only ophthalmic pharmaceutical company in France authorised to operate a tissue bank (link to innovation page with Tissue Bank inset), we cover the main therapeutic segments of our speciality and stand out as solution makers for patients and healthcare professionals.
    Our approach relies on a detailed understanding of the needs of physicians and patients, built through close relationships.

20 years of innovation for eye health

  • 2003

    It all began in 2003, when Horus Pharma stood out by developing the first preservative-free hyaluronic acid drops for dry eye.

    Timeline 2003
  • 2006

    In 2006, a key milestone was reached when the treatment became eligible for reimbursement by the French national health insurance system, a first for a pharmaceutical company and a testament to our commitment to accessible healthcare.

    En 2006, Une étape Décisive Est Franchie
  • 2008

    In 2008, we established operations in Paris at the Institut de la Vision, one of Europe’s leading ophthalmology research centres, further strengthening our ties with academic research and healthcare professionals. This environment strengthens our scientific expertise and guides Horus Pharma’s future developments.

    Horus Pharma Timeline Laboratoire 1160 X 550 Px
  • 2010

    2010 marked the beginning of Horus Pharma’s international expansion with its first distribution partnerships abroad. This momentum culminated in 2015 with the opening of our first subsidiary in Spain, further establishing our presence in Europe.

    Timeline 2010
  • 2018

    In 2018, two major launches strengthened Horus Pharma’s positioning in segments neglected by the pharmaceutical industry: lyophilised amniotic membranes and an intravitreal implant for patients with diabetic macular oedema.

    Timeline 2018
  • 2023

    2023 opened a new chapter for Horus Pharma: selected for ETincelles, a government programme and a true springboard for SMEs, the company launched Clarté Laboratoire.  This new entity dedicated to eye and facial contour care, developed from ophthalmological research, offers a range of high-end cosmetic products.

    Horuspharma Histoire Clarté 2023 1160 X 550 Px
  • 2024

    In 2024, Horus Pharma strengthened its holistic approach to eye health with the creation of dulcis health science, a scientific research laboratory specialising in dietary supplements designed to support eye health and products for eyelid hygiene and care aimed at improving patients’ quality of life.

    Timeline 2024

What sets us apart: products covering the full spectrum of eye conditions

Now the second-largest independent pharmaceutical company in France and a major player in Europe, Horus Pharma has built recognised expertise in innovations that combine efficacy and safety, offering advanced solutions and preservative-free product ranges.

Thanks to our five product categories (medicines, medical devices, human tissues, dietary supplements and cosmetics), our products cover the full range of ophthalmology-related needs, including in niche segments.

Every day, 240 employees now work to bring our 70 products to market. Among them, 20 pharmacists and three ophthalmologists help our sales force better understand the needs of healthcare professionals and their patients. Each year, we devote 10% of our revenue to research and the development of new solutions.

  • Horus Pharma Pictos Statuts ENG Medecines 1000 X 1000 Px
  • Horus Pharma Pictos Statuts ENG Medical Devices 1000 X 1000 Px
  • Horus Pharma Pictos ENG Tissus D’origine Humaine 1000 X 1000 Px
  • Horus Pharma Pictos Statuts ENG Dietary Supplements 1000 X 1000 Px
  • Horus Pharma ENG Cosmetics 1000 X 1000 Px

The status of human tissues:
a distinctive feature of Horus Pharma

Horus Pharma is the only ophthalmic pharmaceutical company in France authorised by the ANSM* to distribute human tissues.

Derived from the human placenta and containing growth factors, lyophilised amniotic membranes are recovered by caesarean section or vaginal delivery and treated through double viral inactivation and sterilisation to eliminate any risk of contamination. Thanks to their healing properties, they are used in many surgical indications in ophthalmology.

*ANSM: Agence Nationale de Sécurité des Médicaments et des produits de santé / National Agency for the Safety of Medicines and Health Products

Looking ahead: development priorities for the challenges of our time

Horus Pharma Texte+image Femme âgée 1200 X 800 Px

Aware of current therapeutic, economic and environmental challenges, we continue to develop solutions that address the major issues of our time.

Our approach to innovation

  • An aging population, pollution, prolonged screen time...

    Factors such as the ageing of the population, pollution and prolonged exposure to digital screens are leading to an increase in chronic eye diseases and the need for adapted care.

  • In a context marked by regulatory constraints

    Amid regulatory constraints specific to the pharmaceutical sector and recurring supply-chain disruptions, Horus Pharma strives to remain agile and responsive.

  • Finally, determined to take action for the environment

    Lastly, determined to take action for the environment, we integrate an eco-responsible approach from the design stage, aiming to minimise the ecological footprint of Horus Pharma products throughout their life cycle.